NCT03091400View on ClinicalTrials.gov

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 16, 2017

Primary Completion Date

June 11, 2018

Study Completion Date

June 11, 2018

Conditions
Memory DisordersMultiple Sclerosis
Interventions
DRUG

Atomoxetine

Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)

DRUG

Placebo

Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03091400 - Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS) | Biotech Hunter | Biotech Hunter